Qualigen Therapeutics, Inc.
QLGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 4.4% | -11.9% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | -0.1% | 13.7% | 23.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -217.1% | -277.7% | -395.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -257.8% | -422.1% | -316.6% |
| EPS Diluted | -17.28 | -2.46 | -5.48 | -6.1 |
| % Growth | -602.4% | 55.1% | 10.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |